Deucravacitinib is a tyrosine kinase 2 inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Deucravacitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for: • the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use: Not recommended for use in combination with other potent immunosuppressants. • the treatment of active psoriatic arthritis in adults.
Source: US FDA prescribing information
Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. JAK kinases, including TYK2, function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways and also pairs with JAK2 to transmit signals as shown in cell-based assays. The precise mechanism linking inhibition of TYK2 enzyme to treatment of moderate-to-severe plaque psoriasis or active psoriatric arthritis is not currently known.
Source: US FDA prescribing information
• For recommended evaluation prior to SOTYKTU initiation, see Full Prescribing Information. • Recommended dosage is 6 mg orally once daily, with or without food.
Source: US FDA prescribing information
SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU. History of hypersensitivity reaction to deucravacitinib or any of the excipients in SOTYKTU.
Source: US FDA prescribing information
• Hypersensitivity Reactions: Hypersensitivity reactions, such as angioedema, have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs. • Infections: SOTYKTU may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue SOTYKTU until the infection resolves. • Tuberculosis: Evaluate for latent or active TB prior to initiating treatment with SOTYKTU. • Malignancy: Malignancies including lymphomas were observed in clinical trials with SOTYKTU. Consider the benefits and risks prior to initiating or continuing SOTYKTU in patients with a malignancy. • Rhabdomyolysis and Elevated CPK: Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. • Laboratory Abnormalities: Periodically evaluate serum triglycerides.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of labeling: • Infections • Malignancy including Lymphomas • Elevated CPK • Laboratory Abnormalities Most common adverse reactions (≥ 1%) are: upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne.
Source: US FDA prescribing information
Store SOTYKTU tablets at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Deucravacitinib, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Sotyktu 6 mg tabletOral | ER Squibb & Sons | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Deucravacitinib in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Deucravacitinib and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Deucravacitinib, including Sotyktu.
Yes. The US FDA first approved Deucravacitinib on 9 September 2022, according to Drugs@FDA.
Yes. Deucravacitinib has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Deucravacitinib is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Deucravacitinib is classified under ATC code L04AF07 (Deucravacitinib).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.